Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

maturity-onset diabetes of the young type 2 News | Kisho

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

A multicenter retrospective study evaluates the long-term effects of lobeglitazone on renal function and albuminuria in Korean patients with type 2 diabetes mellitus. The findings contribute to understanding the drug's impact on kidney health in this population.

A recent study highlights the impact of intraductal papillary mucinous neoplasm on glycemic control in a patient with type 2 diabetes mellitus. This research underscores the need for further investigation into the relationship between pancreatic neoplasms and diabetes management.

A case report highlights the occurrence of insulinoma complicated by hypergastrinemia in a patient with type 2 diabetes mellitus. This finding may provide insights into the complex interactions between these conditions.

Pfizer has entered a deal with Sciwind Biosciences potentially worth up to $495 million to license Ecnoglutide, which is approved in China for type 2 diabetes mellitus. The drug's marketing application for weight loss has also been accepted by Chinese regulatory authorities.

Not rare diseases news,news about your rare disease.

Earlier

A multicenter retrospective study evaluates the long-term effects of lobeglitazone on renal function and albuminuria in Korean patients with type 2 diabetes mellitus. The findings contribute to understanding the drug's impact on kidney health in this population.

A recent study highlights the impact of intraductal papillary mucinous neoplasm on glycemic control in a patient with type 2 diabetes mellitus. This research underscores the need for further investigation into the relationship between pancreatic neoplasms and diabetes management.

A case report highlights the occurrence of insulinoma complicated by hypergastrinemia in a patient with type 2 diabetes mellitus. This finding may provide insights into the complex interactions between these conditions.

Pfizer has entered a deal with Sciwind Biosciences potentially worth up to $495 million to license Ecnoglutide, which is approved in China for type 2 diabetes mellitus. The drug's marketing application for weight loss has also been accepted by Chinese regulatory authorities.

Not rare diseases news,
news about your rare disease.